SCHEMBL4184585

SCHEMBL4184585

O=C(O)/C=N/Nc1cccc(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
LMNA P02545 5/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
GAA P10253 3/20 0.55
RAB9A P51151 6/20 0.51
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
NPC1 O15118 4/20 0.51
HTT P42858 3/20 0.51
ALDH1A1 P00352 3/20 0.51
CYP3A4 P08684 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CISD1 Q9NZ45 1/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4184589 1.00 MAPT (0.55) MAPTLMNASMN1; SMN2GAARAB9A
SCHEMBL28508988 0.85 MAPT (0.57) MAPTLMNASMN1; SMN2GAARAB9A
SCHEMBL23367545 0.84 MAPT (0.47) MAPTLMNASMN1; SMN2GAARAB9A
SCHEMBL6259354 0.83 MAPT (0.51) MAPTLMNASMN1; SMN2GAARAB9A
SCHEMBL2956142 0.80 MAPT (0.54) MAPTSMN1; SMN2GAARAB9AMEN1
SCHEMBL2956145 0.80 MAPT (0.54) MAPTSMN1; SMN2GAARAB9AMEN1
SCHEMBL14059186 0.80 FNTA (0.48) MAPTLMNAGAARAB9AMEN1
SCHEMBL14059185 0.80 FNTA (0.48) MAPTLMNAGAARAB9AMEN1
SCHEMBL1062674 0.80 NOX1 (0.52) MAPTLMNASMN1; SMN2GAARAB9A
SCHEMBL6420581 0.80 NOX1 (0.52) MAPTLMNASMN1; SMN2GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090111857-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 US disclosed
WO-2009054785-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111857-A1 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 GRM5, GRIK5, GRM1 MAPT 770/4885LMNA 4701/4885SMN1; SMN2 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.